Edwards Lifesciences Corp (EW) Company Profile & Statistics

Edwards Lifesciences Corp
EW
(NYSE)
Closed
85.91
-0.54 (-0.63%)
in:usd•As of: Apr 19, 2024 15:59 UTC -4
Open
86.73
High
87.15
Low
85.40

About Edwards Lifesciences Corp

CEO

Bernard J. Zovighian

Headquarters

one edwards way

irvine, ca 92614, united states

Auditor

PricewaterhouseCoopersLLP

Employees

19,800

Share Holders

7,599

Website

www.edwards.com

Industry

medical specialties

Sector

health technology

Company Overview

Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.

Edwards Lifesciences Corp Statistics

Valuation Measures

Market Capitalization ²	51.71B
Enterprise Value	51.16B
Enterprise Value/EBITDA (ttm)	30.47
Price to Earnings Ratio (ttm)	34.76
Price to Book (mrq)	7.87
Price to Sales (ttm)	8.75
Price to Cash (ytd)	31.57

Profitability

Gross Margin (ttm)	77.02%
Operating Margin (ttm)	25.46%
Profit Margin (ttm)	23.38%
Return on Equity (ttm)	23.56%
Return on Invested Capital (ttm)	19.74%
Return on Assets (ttm)	16.81%

Income Statement

Revenue (ttm)	6.00B
Revenue Per Share (ttm)	9.99
Gross Profit (ttm)	4.63B
EBITDA (ttm)³	1.68B
Net Income Avi to Common (ttm)	1.40B
Diluted EPS (ttm)	2.30

Share Statistics

Beta (5Y Monthly)	1.05
52-Week Change	-0.68%
S&P500 52-Week Change	19.56%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	601.30M
Dividend Yield	0.00%
Float ⁴	594.16M
% Held by Insiders	1.29%
% Held by Institutions	79.46%

Balance Sheet

Total Cash (mrq)	1.64B
Total Cash Per Share (mrq)	2.73
Total Debt (mrq)	597.00M
Total Debt/Equity (mrq)	8.88%
Current Ratio (mrq)	3.38%
Quick Ratio (mrq)	2.40%
Book Value Per Share (mrq)	11.18

Cash Flow

Operating Cash Flow Per Share (ytd)	1.47
Free Cash Flow (ytd)	642.80M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Edwards Lifesciences Corp

Trade With A Regulated Broker